Dr. Mitchell Levy, MD

NPI: 1396785325
Total Payments
$24,597
2022 Payments
$900.00
Companies
8
Transactions
10
Medicare Patients
166
Medicare Billing
$47,734

Payment Breakdown by Category

Consulting$12,627 (51.3%)
Research$7,770 (31.6%)
Other$4,200 (17.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $12,627 6 51.3%
Unspecified $7,770 2 31.6%
Honoraria $2,400 1 9.8%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,800 1 7.3%

Payments by Type

General
$16,827
8 transactions
Research
$7,770
2 transactions

Top Paying Companies

Company Total Records Latest Year
Regeneron Pharmaceuticals, Inc. $7,770 2 $0 (2020)
SANOFI US SERVICES INC. $6,252 2 $0 (2020)
Teva Pharmaceuticals USA, Inc. $3,375 1 $0 (2020)
PFIZER INC. $2,400 1 $0 (2021)
SANOFI PASTEUR INC. $1,800 1 $0 (2021)
Janssen Research & Development, LLC $1,500 1 $0 (2020)
Siemens Medical Solutions USA, Inc. $900.00 1 $0 (2022)
BAXTER HEALTHCARE $600.00 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2022 $900.00 1 Siemens Medical Solutions USA, Inc. ($900.00)
2021 $4,200 2 PFIZER INC. ($2,400)
2020 $18,897 6 Regeneron Pharmaceuticals, Inc. ($7,770)
2019 $600.00 1 BAXTER HEALTHCARE ($600.00)

All Payment Transactions

10 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
10/07/2022 Siemens Medical Solutions USA, Inc. Consulting Fee Cash or cash equivalent $900.00 General
10/02/2021 SANOFI PASTEUR INC. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,800.00 General
01/15/2021 PFIZER INC. Honoraria Cash or cash equivalent $2,400.00 General
12/23/2020 SANOFI US SERVICES INC. KEVZARA (Biological) Consulting Fee Cash or cash equivalent $2,605.00 General
Category: Immunology
12/16/2020 Teva Pharmaceuticals USA, Inc. COPAXONE (Drug) Consulting Fee Cash or cash equivalent $3,375.00 General
Category: Central Nervous System
12/11/2020 Regeneron Pharmaceuticals, Inc. KEVZARA (Biological) Cash or cash equivalent $840.00 Research
Study: An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19 • Category: INFLAMMATION AND IMMUNOLOGY
08/07/2020 Regeneron Pharmaceuticals, Inc. KEVZARA (Biological) Cash or cash equivalent $6,930.00 Research
Study: An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19 • Category: INFLAMMATION AND IMMUNOLOGY
08/03/2020 SANOFI US SERVICES INC. KEVZARA (Biological) Consulting Fee Cash or cash equivalent $3,647.00 General
Category: Immunology
05/15/2020 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $1,500.00 General
04/03/2019 BAXTER HEALTHCARE Fluid Systems - Drug Delivery Systems (Biological) Consulting Fee Cash or cash equivalent $600.00 General
Category: Fluid Systems

Research Studies & Clinical Trials

Study Name Company Amount Records
An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19 Regeneron Pharmaceuticals, Inc. $7,770 2

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 1 14 36 $18,082 $6,159
2022 1 25 36 $18,288 $6,363
2021 2 55 102 $47,832 $16,455
2020 2 72 113 $55,714 $18,758
Total Patients
166
Total Services
287
Medicare Billing
$47,734
Procedure Codes
6

All Medicare Procedures & Services

6 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99291 Critical care, first 30-74 minutes Facility 2023 14 36 $18,082 $6,159 34.1%
99291 Critical care, first 30-74 minutes Facility 2022 25 36 $18,288 $6,363 34.8%
99291 Critical care delivery critically ill or injured patient, first 30-74 minutes Facility 2021 41 83 $43,207 $14,844 34.4%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 14 19 $4,625 $1,612 34.8%
99291 Critical care delivery critically ill or injured patient, first 30-74 minutes Facility 2020 54 91 $50,324 $16,846 33.5%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 18 22 $5,390 $1,912 35.5%

About Dr. Mitchell Levy, MD

Dr. Mitchell Levy, MD is a Critical Care Medicine healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396785325.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mitchell Levy, MD has received a total of $24,597 in payments from pharmaceutical and medical device companies, with $900.00 received in 2022. These payments were reported across 10 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($12,627).

As a Medicare-enrolled provider, Levy has provided services to 166 Medicare beneficiaries, totaling 287 services with total Medicare billing of $47,734. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.

Practice Information

  • Specialty Critical Care Medicine
  • Location Providence, RI
  • Active Since 06/07/2006
  • Last Updated 07/26/2018
  • Taxonomy Code 207RC0200X
  • Entity Type Individual
  • NPI Number 1396785325

Products in Payments

  • KEVZARA (Biological) $14,022
  • COPAXONE (Drug) $3,375
  • Fluid Systems - Drug Delivery Systems (Biological) $600.00

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Critical Care Medicine Doctors in Providence